Abstract:To minimize premature release of drugs from their carriers during circulation in the blood stream, we have recently developed reversible disulfide cross-linked micelles (DCMs) that can be triggered to release drug at the tumor site or in cancer cells. We designed and synthesized thiolated linear-dendritic polymers (telodendrimers) by introducing cysteines to the dendritic oligo-lysine backbone of our previously reported telodendrimers comprised of linear polyethylene glycol (PEG) and a dendritic cluster of cholic acids. Reversibly cross-linked micelles were then prepared by the oxidization of thiol groups to disulfide bond in the core of micelles after the self-assembly of thiolated telodendrimers. The DCMs were spherical with a uniform size of 28 nm, and were able to load paclitaxel (PTX) in the core with superior loading capacity up to 35.5% (w/w, drug/micelle). Cross-linking of the micelles within the core reduced their apparent critical micelle concentration and greatly enhanced their stability in non-reductive physiological conditions as well as severe micelle-disrupting conditions. The release of PTX from the DCMs was significantly slower than that from non-cross-linked micelles (NCMs), but can be gradually facilitated by increasing the concentration of reducing agent (glutathione) to an intracellular reductive level. The DCMs demonstrated a longer in vivo blood circulation time, less hemolytic activities, and superior toxicity profiles in nude mice, when compared to NCMs. DCMs were found to be able to preferentially accumulate at the tumor site in nude mice bearing SKOV-3 ovarian cancer xenograft. We also demonstrated that the disulfide cross-linked micellar formulation of PTX (PTX-DCMs) was more efficacious than both free drug and the non-cross-linked formulation of PTX at equivalent doses of PTX in the ovarian cancer xenograft mouse model. The anti-tumor effect of PTX-DCMs can be further enhanced by triggering the release of PTX on-demand by the administration of the FDA approved reducing agent, N-acetylcysteine, after PTX-DCMs have reached the tumor site.

Improved Antitumor Activity of Novel Redox-Responsive Paclitaxel-Encapsulated Liposomes Based on Disulfide Phosphatidylcholine

Redox-sensitive Dimeric Paclitaxel Choline Phosphate Nanoliposomes for Improved Anticancer Efficacy

Bio-responsive Bletilla Striata Polysaccharide-Based Micelles for Enhancing Intracellular Docetaxel Delivery

Reduction Responsive Liposomes Based on Paclitaxel-Ss-lysophospholipid with High Drug Loading for Intracellular Delivery.

Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy

Disulfide-crosslinked Reduction-Responsive Prodrug Micelles for On-demand Paclitaxel Release

Prodrug Micelles Based on Norbornene-Functional Poly(lactide)s Backbone for Redox-Responsive Release of Paclitaxel

Tumor-targeted Paclitaxel Delivery and Enhanced Penetration Using TAT-decorated Liposomes Comprising Redox-Responsive Poly(ethylene Glycol).

Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Rational Design of Redox-Responsive and P-gp-Inhibitory Lipid Nanoparticles with High Entrapment of Paclitaxel for Tumor Therapy.

Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy

Biological Evaluation of Redox-Sensitive Micelles Based on Hyaluronic Acid-Deoxycholic Acid Conjugates for Tumor-Specific Delivery of Paclitaxel.

Redox-Sensitive Micelles Based on O,N-Hydroxyethyl Chitosan-Octylamine Conjugates for Triggered Intracellular Delivery of Paclitaxel

Well-defined Polymer-Drug Conjugate Engineered with Redox and Ph-Sensitive Release Mechanism for Efficient Delivery of Paclitaxel.

Reduction-sensitive Dual Functional Nanomicelles for Improved Delivery of Paclitaxel.

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug

Simple Weak-Acid Derivatives of Paclitaxel for Remote Loading into Liposomes and Improved Therapeutic Effects

Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery.

Redox-responsive Prodrug for Improving Oral Bioavailability of Paclitaxel Through Bile Acid Transporter-Mediated Pathway.

Histology and Antitumor Activity Study of PTX-loaded Micelle, a Fluorescent Drug Delivery System Prepared by PEG-TPP